Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus

被引:60
作者
Janka, Hans U.
Plewe, Gerd
Busch, Klaus
机构
[1] Klinikum Bremen Nord, Med Abt 2, D-28755 Bremen, Germany
[2] Diabetol Schwerpunktpraxis, Dortmund, Germany
关键词
insulin glargine; premixed insulin; type 2 diabetes mellitus;
D O I
10.1111/j.1532-5415.2007.01043.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To compare initiation of insulin therapy by adding once-daily insulin glargine to oral antidiabetic agents (OADs) with switching patients to premixed 30% regular, 70% human neutral protamine hagedorn insulin (70/30) without OADs. DESIGN: A 24-week, multicenter, open, randomized (1:1), parallel study. SETTING: Three hundred sixty-four poorly controlled patients with type 2 diabetes mellitus were treated with once-daily morning insulin glargine with continued OADs (glimepiride+metformin) (glargine+OAD) or twice-daily 70/30 alone. Insulin dosage in each group was titrated to target fasting blood glucose (FBG) of 100 mg/dL or less (<= 5.6 mmol/L) using a weekly titration algorithm. PARTICIPANTS: This planned subgroup analysis of the original study was based on 130 insulin-naive patients aged 65 and older with FBG of 120 mg/dL or greater (>= 6.7 mmol/L) and hemoglobin (Hb)A(1c) levels between 7.5% and 10.5% on OADs (glargine+OAD, n=67; 70/30, n=63). MEASUREMENTS: HbA(1c), FBG, hypoglycemia, insulin dose, and adverse events were recorded. RESULTS: HbA(1c) decreased from baseline to endpoint for both glargine+OAD (from 8.8% to 7.0%) and 70/30 (from 8.9% to 7.4%); adjusted mean HbA(1c) decrease for glargine+OAD and 70/30 was -1.9% and -1.4%, respectively (P=.003). More patients reached HbA(1c) of 7.0% or less without confirmed nocturnal hypoglycemia with glargine+OAD (n=37, 55.2%) than with 70/30 (n=19, 30.2%) (P=.006). FBG decreased significantly more with glargine+OAD (-57 mg/dL (-3.2 mmol/L)) than with 70/30 (-40 mg/dL (-2.2 mmol/L)) (P=.002). Patients treated with glargine+OAD experienced fewer episodes of any hypoglycemia (3.68/patient-year) than did those treated with 70/30 (9.09/patient-year) (P=.008). CONCLUSION: In elderly patients, addition of once-daily morning glargine+OAD is a simple regimen to initiate insulin therapy, restoring glycemic control more effectively and with less hypoglycemia than twice-daily 70/30 alone.
引用
收藏
页码:182 / 188
页数:7
相关论文
共 20 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]  
[Anonymous], 1999, Diabet Med, V16, P716
[3]  
[Anonymous], 1996, DIABETES, V45, P1289
[4]  
[Anonymous], 2002, Diabetes care, V25, pS1
[5]   Novel drug delivery systems for insulin - Clinical potential for use in the elderly [J].
Belmin, J ;
Valensi, P .
DRUGS & AGING, 2003, 20 (04) :303-312
[6]  
Cefalu WT, 2002, AM J MED, V113, p23S
[7]   Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study [J].
Dills, DG ;
Schneider, J ;
Aronoff, SL ;
Azorr, MA ;
Brunner, D ;
Cefalu, WT ;
Cohen, AJ ;
Cyrus, J ;
Freedman, Z ;
Haag, BL ;
Hamilton, BP ;
Littlejohn, TW ;
Lucas, CP ;
Matlock, JS ;
McGill, JB ;
Miller, SS ;
Nikolai, T ;
Ogilvie, JT ;
Podlecki, DA ;
Ricaurte, M ;
Roudebush, CP ;
Singh, SP ;
Smulovitz, J ;
Soler, NG ;
Stone, J ;
Stonesifer, LD ;
Tucker, WS ;
Wallum, BJ ;
White, J ;
Whittier, FC ;
Zieve, FJ .
HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :426-429
[8]  
Fritsche A, 2003, DIABETES, V52, pA119
[9]  
GOSSAIN VV, 1987, J ASS ACAD MINOR PHY, V5, P22
[10]   Comparative efficacy of preprandial or postprandial Humalog® Mix75/25™ versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus [J].
Herz, M ;
Sun, B ;
Milicevic, Z ;
Erickson, P ;
Fövènyi, J ;
Grzywa, M ;
Pelikanova, T .
CLINICAL THERAPEUTICS, 2002, 24 (01) :73-86